Dana McClintock, MD

Dr. McClintock is currently the Chief Medical Officer at Alladapt Immunotherapeutics, Inc., a role she’s held since 2018. She is also currently a member of the  clinical and scientific advisory board of Vasomune Therapeutics.  Prior to joining Alladapt, Dr. McClintock was Global Head of Innovation for Immunology, Infectious Disease and Ophthalmology at Genentech/Roche. Her responsibilities included accelerating use of emergent technologies and enabling novel approaches to clinical development with a focus on pediatrics. Prior to this role, Dr. McClintock, held roles of increasing responsibility at Genentech/Roche, including Global Head of Pipeline and Portfolio planning for Immunology, Infectious Disease and Ophthalmology as well as Interim Global Co-Head of Ophthalmology.

Earlier in Dr. McClintock’s pharmaceutical career, she was deeply involved in respiratory, immunology and ophthalmology clinical development activities across a range of phases, from IND-enabling work and early clinical trials through post-marketing commitments and medical affairs activities. Dr. McClintock was involved in key clinical development activities for omalizumab (Xolair) and ranibizumab (Lucentis) as well as other pipeline molecules.  Prior to joining the pharmaceutical industry, Dr. McClintock’s academic research focus was in ARDS, with publications evaluating ventilator parameters as well plasma biomarkers of epithelial and endothelial cell injury. 

Dr. McClintock received her BA in Chemistry from Duke University and her MD from the University of Virginia School of Medicine. Dr. McClintock completed both her Internal Medicine residency and Pulmonary and Critical Care fellowship at the University of California, San Francisco.